PITTSBURGH, June 20, 2025 (WORLD NEWSWIRE)– Lipella Pharmaceuticals Inc. LIPO (” Lipella” or the “Business”), a clinical-stage biotechnology business concentrated on establishing treatments for illness with considerable unmet requirements, today revealed that the Nasdaq Hearings Panel has actually identified to delist the Business’s typical stock from The Nasdaq Capital Market. Trading in the typical stock was suspended at the open of organization today.
The delisting follows Nasdaq’s decision that specific personal positioning deals finished in between December 2024 and March 2025 did not adhere to Noting Guidelines 5100 (Public Interest Issue), 5635 (Investor Approval), and 5640 (Ballot Rights). Particularly, Nasdaq pointed out the issuance of Series C voting convertible favored stock and warrants to the Business’s positioning representative and consultant to those deals, as having actually been structured in such a way that activated these guideline offenses.
The Business was informed by the Hearings Panel of its decision to delist the Business’s typical stock efficient today. Lipella is dissatisfied by this choice– especially due to the reality that it was taking instant actions to get shareholder approval and resolve the issues raised by Nasdaq.
Lipella stays operationally sound, and its organization principles are undamaged. The Business is carrying out on its tactical and medical advancement strategies, consisting of continued improvement of its lead item prospects LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus.
In parallel, Lipella is actively checking out other markets to note its typical stock and is dedicated to relisting its shares on a trading place that supplies the very best possible liquidity and gain access to for financiers. The Business’s typical stock is presently estimated on the OTC Markets under the sign “LIPO.”
” We acknowledge Nasdaq’s choice and are concentrated on taking swift, positive actions appropriately,” stated Dr. Jonathan Kaufman, President of Lipella. “Our dedication to our investors, our objective, and our medical objectives has actually not altered.”
The Business stays a reporting business under the Securities Exchange Act of 1934 and will continue to submit routine reports and disclosures with the U.S. Securities and Exchange Commission. Lipella will keep its investors notified of all product advancements as it continues to examine its alternatives.
About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals is a clinical-stage biotechnology business concentrated on establishing brand-new drugs by reformulating active representatives in existing generic drugs and enhancing these reformulations for brand-new applications. Lipella targets illness with considerable unmet requirements, where no authorized drug treatments presently exist. The business finished its going public in 2022. Discover more at lipella.com and follow us on X and LinkedIn
Positive Declarations
This news release consists of specific “positive declarations.” All declarations, besides declarations of historic reality, consisted of in this news release concerning, to name a few things, our technique, consisting of with regard to the Business’s expedition of all markets and its dedication to note its typical stock, future operations, monetary position, potential customers, medical trials, regulative approvals, pipeline and chances, sources of development, effective execution of our exclusive innovation, strategies and goals are positive declarations. Positive declarations can be determined by words such as “may,” “will,” “could,” “continue,” “would,” “should,” “prospective,” “target,” “objective,” “prepares for,” “means,” “strategies,” “looks for,” “thinks,” “quotes,” “anticipates,” “anticipates,” “tasks” and comparable recommendations to future durations. Positive declarations are based upon our existing expectations and presumptions concerning future occasions and monetary patterns that our company believe might impact to name a few things, market and other conditions, our monetary condition, outcomes of operations, organization technique, brief- and long-lasting organization operations and goals, and monetary requirements. Since positive declarations connect to the future, they go through intrinsic unpredictabilities, threats and modifications in scenarios that are tough to forecast. Our real outcomes might vary materially from those considered by the positive declarations. We warn you, for that reason, versus counting on any of these positive declarations. They are neither declarations of historic reality nor warranties or guarantees of future efficiency. There are threats, unpredictabilities and other elements, both recognized and unidentified, that might trigger real outcomes to vary materially from those in the positive declarations that include, however are not restricted to, basic capital market threats, local, nationwide or international political, financial, organization, competitive, market and regulative conditions, and other threats that might be consisted of in the routine reports and other filings that the Business files from time to time with the U.S. Securities and Exchange Commission. Any positive declaration made by us is based upon the sensible judgment of our management at the time such declaration is made and speaks just since the date on which it is made. Aspects or occasions that might trigger our real outcomes to vary might emerge from time to time, and it is not possible for us to forecast all of them. We carry out no responsibility to upgrade any positive declaration, whether as an outcome of brand-new details, future advancements or otherwise, other than as might be needed by suitable law. Absolutely nothing consisted of herein is, or will be trusted as, a pledge or representation regarding the past or future. In addition, the details consisted of in this news release is since the date hereof, and the Business has no responsibility to upgrade such details, consisting of in case such details ends up being unreliable. You need to not interpret the contents of this news release as legal, tax and monetary consultants regarding legal and associated matters worrying the matters explained herein.
CONTACT:
Jonathan Kaufman
President
Lipella Pharmaceuticals Inc.
Info@Lipella.com
1-412-894-1853
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com